S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
An Unusual Way to Invest in Gold (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
META's Outperformance Last Week Points to Imminent Breakout
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
An Unusual Way to Invest in Gold (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
META's Outperformance Last Week Points to Imminent Breakout
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
An Unusual Way to Invest in Gold (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
META's Outperformance Last Week Points to Imminent Breakout
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Blue Chip Safe Havens to Shield Your Portfolio
Would Buffett Approve of This Growth Strategy? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
3 Stocks That Flourish In The Fall
An Unusual Way to Invest in Gold (Ad)
Stock market today: Wall Street inches lower hinting that sustained market sell-off may continue
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
An Unusual Way to Invest in Gold (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
META's Outperformance Last Week Points to Imminent Breakout
Lowest-Rated StocksLowest-Rated
NYSE:GSK

GSK (GSK) Stock Forecast, Price & News

$37.43
-0.19 (-0.51%)
(As of 08:34 AM ET)
Compare
Today's Range
$37.43
▼
$37.43
50-Day Range
$34.18
▼
$38.07
52-Week Range
$28.47
▼
$39.74
Volume
3,618 shs
Average Volume
3.34 million shs
Market Capitalization
$76.64 billion
P/E Ratio
4.27
Dividend Yield
3.77%
Price Target
$37.27
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

GSK MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.4% Downside
$37.27 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.49mentions of GSK in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
1.86%
From $3.77 to $3.84 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

625th out of 961 stocks

Pharmaceutical Preparations Industry

288th out of 456 stocks

See Top Rated MarketRank™ Stocks Here

GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

GSK Price History

GSK Stock News Headlines

September 25, 2023 | lse.co.uk
TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan
September 25, 2023 | markets.businessinsider.com
GSK Plc Announces Approval Of Arexvy In Japan - Quick Facts
September 25, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
September 25, 2023 | reuters.com
BRIEF-GSK Says RSV Vaccine For Older Adults Approved In Japan
September 22, 2023 | msn.com
Was selling our GSK shares a big mistake?
September 22, 2023 | seekingalpha.com
Merck Vs. GSK: The Game-Changer Race In Pharma Excellence
September 21, 2023 | msn.com
GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia
September 21, 2023 | msn.com
GSK subsidiary ViiV gets EU okay for HIV prevention drug
September 25, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
September 20, 2023 | reuters.com
European Commission authorises GSK's HIV prevention drug
September 20, 2023 | foxnews.com
European Commission authorizes GSK's HIV prevention drug
September 19, 2023 | msn.com
FDA approves GSK drug Ojjaara for myelofibrosis with anemia
September 18, 2023 | markets.businessinsider.com
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 17, 2023 | marketwatch.com
GSK Gets FDA OK on Treatment for Myelofibrosis Patients with Anemia
September 17, 2023 | msn.com
CORRECTED-UPDATE 2-US FDA approves GSK's bone marrow cancer therapy
September 17, 2023 | msn.com
GSK Secures FDA Approval for New Blood Cancer Treatment
September 17, 2023 | news.yahoo.com
EU regulator recommends stopping sale of GSK's blood cancer drug
September 15, 2023 | finance.yahoo.com
UPDATE 2-US FDA approves GSK's bone marrow cancer therapy
September 15, 2023 | msn.com
UPDATE 2-EU regulator recommends stopping sale of GSK's blood cancer drug
September 14, 2023 | seekingalpha.com
GSK plc (GSK) Presents at BofA Global Healthcare Conference (Transcript)
September 14, 2023 | uk.finance.yahoo.com
GSK to open £65m drug factory in Hertfordshire
September 13, 2023 | msn.com
Hong Kong will need ‘proper strategy’ for integrating health data for biomedical hub ambitions, pharma giant GSK chair says
September 12, 2023 | msn.com
Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash
September 12, 2023 | forbes.com
How A Pair Of Air Jordans Communicated A Culture Shift
September 12, 2023 | finance.yahoo.com
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
September 7, 2023 | seekingalpha.com
GSK plc (GSK) Citi's 18th Annual BioPharma Conference Transcript
September 4, 2023 | thetimes.co.uk
GSK breathes easy with world-first vaccine for respiratory syncytial virus
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Ex-Dividend for 7/13 Dividend
5/18/2023
Dividend Payable
7/13/2023
Last Earnings
7/26/2023
Ex-Dividend for 10/12 Dividend
8/17/2023
Today
9/25/2023
Dividend Payable
10/12/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:GSK
CUSIP
N/A
CIK
1131399
Web
www.gsk.com
Phone
442080475000
Fax
44-20-8047-7807
Employees
69,400
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$37.27
High Stock Price Forecast
$50.43
Low Stock Price Forecast
$24.44
Forecasted Upside/Downside
-0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$8.76
Trailing P/E Ratio
4.27
Forward P/E Ratio
9.93
P/E Growth
1.98
Net Income
$18.50 billion
Net Margins
50.26%
Pretax Margin
20.26%
Return on Equity
55.93%
Return on Assets
9.94%

Debt

Debt-to-Equity Ratio
1.28
Current Ratio
0.88
Quick Ratio
0.63

Sales & Book Value

Annual Sales
$36.28 billion
Price / Sales
2.11
Cash Flow
$4.46 per share
Price / Cash Flow
8.39
Book Value
$5.79 per share
Price / Book
6.46

Miscellaneous

Outstanding Shares
2,047,510,000
Free Float
1,842,757,000
Market Cap
$76.64 billion
Optionable
Optionable
Beta
0.68

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 53)
    CEO & Director
    Comp: $6.02M
  • Ms. Julie Belita Brown (Age 61)
    CFO & Exec. Director
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally JacksonMs. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 57)
    CA, Pres of Corp. Devel.
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    Pres of Global Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 4 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

What is GSK's stock price forecast for 2023?

8 equities research analysts have issued 1-year target prices for GSK's stock. Their GSK share price forecasts range from $24.44 to $50.43. On average, they expect the company's share price to reach $37.27 in the next year. This suggests that the stock has a possible downside of 0.4%.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 at the start of the year. Since then, GSK stock has increased by 6.5% and is now trading at $37.43.
View the best growth stocks for 2023 here.

Are investors shorting GSK?

GSK saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 4,850,000 shares, a decline of 7.8% from the August 15th total of 5,260,000 shares. Based on an average daily volume of 3,400,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.2% of the shares of the company are short sold.
View GSK's Short Interest.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GSK earnings forecast.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) issued its earnings results on Wednesday, July, 26th. The pharmaceutical company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The pharmaceutical company earned $8.98 billion during the quarter, compared to the consensus estimate of $8.49 billion. GSK had a trailing twelve-month return on equity of 55.93% and a net margin of 50.26%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, July 26th. Stockholders of record on Friday, August 18th will be given a dividend of $0.3613 per share on Thursday, October 12th. This represents a $1.45 dividend on an annualized basis and a dividend yield of 3.86%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for GSK.

What ETFs hold GSK's stock?

ETFs with the largest weight of GSK (NYSE:GSK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), Subversive Mental Health ETF (SANE), Sound Equity Dividend Income ETF (DIVY), Sound Equity Income ETF (SDEI), Pacer BioThreat Strategy ETF (VIRS), Horizon Kinetics Medical ETF (MEDX), Altrius Global Dividend ETF (DIVD) and B.A.D. Etf (BAD).

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.41 per share and currently has a dividend yield of 3.78%. The dividend payout ratio is 16.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $1.99-$2.05 for the period, compared to the consensus earnings per share estimate of $3.80. The company issued revenue guidance of $39.63 billion-$40.37 billion, compared to the consensus revenue estimate of $37.43 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.68%), JTC Employer Solutions Trustee Ltd (0.67%), Royal Bank of Canada (0.38%), State Street Corp (0.35%), Acadian Asset Management LLC (0.21%) and Camber Capital Management LP (0.20%).
View institutional ownership trends.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $37.43.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $76.64 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.76 on an earnings per share basis.

How many employees does GSK have?

The company employs 69,400 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -